By Budi Oetomo Narendra 
Breast cancer screening, a cornerstone of preventive healthcare for women globally, has long been associated with a critical, albeit less understood, phenomenon known as overdiagnosis. This occurs when screening identifies cancers that would never have progressed to cause symptoms, threaten health, or shorten a woman’s life during her natural lifespan. For decades, the true prevalence of overdiagnosis has been a subject of intense scientific debate, with wide-ranging estimates fueling international discussions about the precise balance of benefits and harms in population-based screening programs. However, a groundbreaking new study, drawing on a comprehensive re-analysis of all randomized controlled trials (RCTs) of mammography screening and real-world data from Denmark, suggests that the incidence of overdiagnosis may be substantially lower than widely cited previous figures.
The findings challenge earlier estimates, some of which suggested that between 30% and 50% of screen-detected breast cancers could be overdiagnosed. These higher figures have significantly influenced public perception, clinical guidelines, and the informed consent process for women considering mammography. The new research, spearheaded by academics from the University of Southern Denmark, Lillebælt Hospital, the University of Copenhagen, and Queen Mary University of London, indicates that when trial data are interpreted in their full temporal context, overdiagnosis is likely below 5%. This revised understanding carries profound implications for how the efficacy and value of breast cancer screening are perceived and communicated worldwide.
The Enduring Debate on Overdiagnosis
The concept of overdiagnosis emerged as a critical consideration with the widespread adoption of mammography screening in the latter half of the 20th century. While screening demonstrably saves lives by detecting aggressive cancers at an early, more treatable stage, the simultaneous identification of indolent (slow-growing or non-progressive) cancers presents a unique ethical and clinical dilemma. A woman diagnosed with an overdiagnosed cancer might undergo unnecessary biopsies, surgery, radiation, or chemotherapy, enduring physical and psychological burdens without any corresponding health benefit. This potential for overtreatment has been a primary concern for patients, clinicians, and health policy makers alike.
The scientific community has grappled with quantifying overdiagnosis since its recognition. Early attempts to estimate its frequency often relied on comparing cancer incidence rates in screened populations versus unscreened populations. An initial surge in diagnoses within screened groups, not followed by a corresponding decrease in later stages, was frequently interpreted as evidence of overdiagnosis. However, the complexity of cancer progression, the long natural history of many breast cancers, and the dynamic nature of screening programs introduced significant challenges to accurate measurement. Different methodological approaches and varying assumptions led to a wide spectrum of estimates, from negligible percentages to alarmingly high figures, creating considerable uncertainty.
A New Lens on Established Evidence
"The aim of our study was to bring together the evidence from all randomized controlled trials to get a clearer picture of the extent of overdiagnosis in breast cancer screening," stated Sisse Helle Njor, a professor at the University of Southern Denmark and Lillebælt Hospital, highlighting the comprehensive nature of their work. She further elaborated, "Randomized trials have often been cited as evidence that overdiagnosis is a substantial problem. Our study shows that this interpretation is not as straightforward as it may seem."
The research team undertook a rigorous re-analysis of data from all eight randomized controlled trials of mammography screening ever conducted. These landmark trials, which include the New York Health Insurance Plan, Malmö, Two-County, Edinburgh, the Canadian National Breast Screening Study, Stockholm, Gothenburg, and UK Age, formed the bedrock upon which many national screening guidelines were initially established. By pooling and meticulously re-examining these trials, the researchers sought to overcome the limitations of individual studies and provide a more robust, aggregated estimate.
Crucially, their methodology involved comparing the patterns observed in these trials with real-world data from Denmark. Denmark provided a unique and valuable reference point due to its staggered implementation of organized breast cancer screening programs. In some regions, screening was introduced as much as 17 years earlier than in others, creating a natural experiment that allowed researchers to track the evolution of breast cancer diagnoses immediately following screening introduction and over extended periods. This allowed for a dynamic, time-sensitive analysis that is often difficult to achieve in closed trial settings.
The Critical Role of Timing and Follow-Up
A central tenet of the study’s findings revolves around the critical impact of timing and follow-up duration on overdiagnosis estimates. "When screening is introduced, the number of breast cancer diagnoses initially rises because cancers are detected earlier than they would have been without screening," explained Elsebeth Lynge, professor emerita at the Department of Public Health, University of Copenhagen. "Over time, this should be followed by a drop, as some of these cancers would otherwise have been diagnosed later. This pattern can also be affected if women in either group continue to undergo screening after the trials had ended, which was common. If researchers do not take these factors into account, the initial increase can be mistaken for overdiagnosis."
The original interpretation of many trials often focused on the early surge in diagnoses within screened groups. If a study concluded before a sufficient period had elapsed for the expected subsequent decline in incidence to manifest, researchers might incorrectly attribute a portion of this early increase to overdiagnosis. Furthermore, the contamination of control groups – where women initially assigned to the unscreened group later sought or received screening – could also distort results, masking the true difference in incidence between screened and unscreened populations over the long term.
The new analysis meticulously accounted for these variables, reassessing how differences in screening exposure and follow-up time influenced earlier estimates. By comparing breast cancer incidence at matching points in time across the randomized trials and Denmark’s routine screening programs, the team was able to discern whether the observed patterns were consistent and what those consistencies revealed about the actual scale of overdiagnosis. This comprehensive temporal perspective allowed them to distinguish between a genuine increase in diagnoses due to overdiagnosis and a temporary shift in the timing of diagnosis (lead time bias).
Reconciling Discrepancies: A Unified Picture
"Taken together, we believe some previous high estimates of overdiagnosis, which influenced screening guidelines and communication, were based on evidence before trial data had fully matured," stated Matejka Rebolj, Senior Epidemiologist at Queen Mary University of London. "When interpreted in their full temporal context, randomized trial data are consistent with overdiagnosis of less than five percent, rather than with estimates nearing 50%."
This stark contrast between the previous high estimates and the new, lower figure fundamentally alters the risk-benefit calculus for breast cancer screening. The study specifically examined both invasive breast cancer and ductal carcinoma in situ (DCIS), a non-invasive condition that is often detected by mammography and can sometimes progress to invasive cancer but in other cases may never cause harm. The re-evaluation suggests that even for DCIS, the overdiagnosis rates are lower than previously feared, though DCIS remains an area of ongoing research regarding optimal management.
The researchers found that the additional breast cancer cases detected in randomized trials, when viewed over a sufficiently long follow-up period and adjusted for lead time bias and control group contamination, closely resembled the patterns seen in Denmark. In Denmark, where the long-term effects of screening could be observed due to the staggered regional implementation, the estimated overdiagnosis associated with screening was found to be below 5%. This strong concordance between the re-analyzed trial data and real-world population-level observations lends significant credibility to the new, lower estimates.
Implications for Public Health and Women’s Choices
The implications of these findings are far-reaching. Understanding both the benefits and potential downsides of screening is paramount for women making informed decisions about whether to participate in breast cancer screening programs. For decades, the specter of high overdiagnosis rates has been a source of anxiety for many women, sometimes leading to hesitancy or refusal to engage in screening.
"Most women will not develop breast cancer, but with this study, we can now be reassured that the benefits of detecting breast cancer early and preventing premature death will outweigh the small risk of unnecessary treatment," Professor Njor affirmed. This reassurance is critical for public health campaigns aimed at encouraging appropriate screening participation.
Public health bodies and medical societies globally will likely review their communication strategies and guidelines in light of this new evidence. The emphasis can now shift more confidently towards the life-saving benefits of early detection, while still acknowledging the small, but present, risk of overdiagnosis. This recalibration offers an opportunity to provide women with a more balanced, evidence-based perspective, fostering greater trust in screening programs. The reduced uncertainty regarding overdiagnosis may also influence clinical practice, potentially guiding discussions around surveillance versus immediate intervention for certain low-risk screen-detected lesions.
Funding and Future Directions
The rigorous re-analysis was made possible through dedicated funding, with Casper Urth Pedersen supported by the Novo Nordisk Foundation (reference: NNF22OC0076184) and Matejka Rebolj supported by Cancer Research UK (reference: C8162/A29083). Such investments are vital for advancing scientific understanding and refining medical practices.
While this study provides a significant step forward in understanding overdiagnosis, research in this complex area is ongoing. Further studies may delve deeper into specific tumor characteristics to better predict which cancers are truly indolent and which require intervention. Improved diagnostic tools and personalized risk assessment models could also contribute to minimizing overdiagnosis while maximizing the benefits of screening.
Ultimately, this research provides a framework for a more realistic interpretation of the evidence. By carefully considering the temporal dynamics of cancer detection and progression, the scientific community can offer clearer, more accurate guidance to women and healthcare providers. The message is one of renewed confidence: the benefits of breast cancer screening in preventing premature death substantially outweigh the now-quantified, small risk of overdiagnosis and subsequent unnecessary treatment. This clarity is invaluable in empowering women to make confident, informed decisions about their health.
